Project description
A novel antibody therapy against non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease is strongly associated with poor nutrition and obesity, often leading to non-alcoholic steatohepatitis (NASH), fibrosis and liver cancer. Anti-platelet therapy has emerged as a potential strategy against NASH but exhibits adverse health effects. Researchers of the EU-funded FAITH project have previously shown that blocking the platelet-derived surface molecule GPIba prevents NASH and liver cancer in experimental models without any side effects. With this project, they plan to generate antibodies to block the binding of thrombin to GPIba without interfering with its role in platelet-derived aggregation and haemostasis.
Fields of science
Programme(s)
Funding Scheme
ERC-POC - Proof of Concept GrantHost institution
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Net EU contribution
€ 150 000,00
Address
Im Neuenheimer Feld 280
69120 Heidelberg
Germany
69120 Heidelberg
Germany
See on map
Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Research Organisations
Other funding
No data
Beneficiaries (1)
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Germany
Net EU contribution
€ 150 000,00
Address
Im Neuenheimer Feld 280
69120 Heidelberg
69120 Heidelberg
See on map
Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Research Organisations
Other funding
No data